133 related articles for article (PubMed ID: 34265289)
1. Evaluation of the anticancer activity of singly and doubly modified analogues of C20-epi-salinomycin.
Czerwonka D; Mielczarek-Puta M; Antoszczak M; Cioch A; Struga M; Huczyński A
Eur J Pharmacol; 2021 Oct; 908():174347. PubMed ID: 34265289
[TBL] [Abstract][Full Text] [Related]
2. Singly and doubly modified analogues of C20-epi-salinomycin: A new group of antiparasitic agents against Trypanosoma brucei.
Czerwonka D; Barcelos Y; Steverding D; Cioch A; Huczyński A; Antoszczak M
Eur J Med Chem; 2021 Jan; 209():112900. PubMed ID: 33071053
[TBL] [Abstract][Full Text] [Related]
3. Activity of singly and doubly modified derivatives of C20-epi-salinomycin against Staphylococcus strains.
Czerwonka D; Podsiad M; Stefańska J; Antoszczak M; Huczyński A
J Antibiot (Tokyo); 2022 Aug; 75(8):445-453. PubMed ID: 35760901
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Anticancer Activity of Tertiary Amides of Salinomycin and Their C20-oxo Analogues.
Czerwonka D; Urbaniak A; Sobczak S; Piña-Oviedo S; Chambers TC; Antoszczak M; Huczyński A
ChemMedChem; 2020 Jan; 15(2):236-246. PubMed ID: 31702860
[TBL] [Abstract][Full Text] [Related]
5. Antibacterial activity of singly and doubly modified salinomycin derivatives.
Sulik M; Stępień K; Stefańska J; Huczyński A; Antoszczak M
Bioorg Med Chem Lett; 2020 May; 30(9):127062. PubMed ID: 32147358
[TBL] [Abstract][Full Text] [Related]
6. Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified salinomycin analogues.
Huang X; Borgström B; Månsson L; Persson L; Oredsson S; Hegardt C; Strand D
ACS Chem Biol; 2014 Jul; 9(7):1587-94. PubMed ID: 24841425
[TBL] [Abstract][Full Text] [Related]
7. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models.
Urbaniak A; Reed MR; Fil D; Moorjani A; Heflin S; Antoszczak M; Sulik M; Huczyński A; Kupsik M; Eoff RL; MacNicol MC; Chambers TC; MacNicol AM
Biomed Pharmacother; 2021 Sep; 141():111815. PubMed ID: 34130123
[TBL] [Abstract][Full Text] [Related]
8. Biological activity of doubly modified salinomycin analogs - Evaluation in vitro and ex vivo.
Antoszczak M; Urbaniak A; Delgado M; Maj E; Borgström B; Wietrzyk J; Huczyński A; Yuan Y; Chambers TC; Strand D
Eur J Med Chem; 2018 Aug; 156():510-523. PubMed ID: 30025346
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.
Michalak M; Lach MS; Antoszczak M; Huczyński A; Suchorska WM
Molecules; 2020 Jan; 25(3):. PubMed ID: 31991882
[TBL] [Abstract][Full Text] [Related]
10. Salinomycin and its derivatives - A new class of multiple-targeted "magic bullets".
Antoszczak M; Huczyński A
Eur J Med Chem; 2019 Aug; 176():208-227. PubMed ID: 31103901
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents.
Antoszczak M
Eur J Med Chem; 2019 Mar; 166():48-64. PubMed ID: 30684870
[TBL] [Abstract][Full Text] [Related]
12. Nanocarrier - Mediated Salinomycin Delivery Induces Apoptosis and Alters EMT Phenomenon in Prostate Adenocarcinoma.
Kanchan S; Marwaha D; Tomar B; Agrawal S; Mishra S; Kapoor R; Sushma ; Jha G; Sharma D; Bhatta RS; Mishra PR; Rath SK
AAPS PharmSciTech; 2024 May; 25(5):104. PubMed ID: 38724836
[TBL] [Abstract][Full Text] [Related]
13. Anti-trypanosomal activity of doubly modified salinomycin derivatives.
Antoszczak M; Steverding D; Sulik M; Janczak J; Huczyński A
Eur J Med Chem; 2019 Jul; 173():90-98. PubMed ID: 30986574
[TBL] [Abstract][Full Text] [Related]
14. Ester derivatives of salinomycin efficiently eliminate breast cancer cells via ER-stress-induced apoptosis.
Kuran D; Flis S; Antoszczak M; Piskorek M; Huczyński A
Eur J Pharmacol; 2021 Feb; 893():173824. PubMed ID: 33347821
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Anticancer Activity of Dimeric Polyether Ionophores.
Sulik M; Maj E; Wietrzyk J; Huczyński A; Antoszczak M
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664671
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.
Huang X; Borgström B; Kempengren S; Persson L; Hegardt C; Strand D; Oredsson S
BMC Cancer; 2016 Feb; 16():145. PubMed ID: 26906175
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of salinomycin triazole analogues as anticancer agents.
Huang M; Deng Z; Tian J; Liu T
Eur J Med Chem; 2017 Feb; 127():900-908. PubMed ID: 27876192
[TBL] [Abstract][Full Text] [Related]
18. Expeditive Synthesis of Potent C20-
Czerwonka D; Müller S; Cañeque T; Colombeau L; Huczyński A; Antoszczak M; Rodriguez R
ACS Org Inorg Au; 2022 Jun; 2(3):214-221. PubMed ID: 35673680
[TBL] [Abstract][Full Text] [Related]
19. A medicinal chemistry perspective on salinomycin as a potent anticancer and anti-CSCs agent.
Antoszczak M
Eur J Med Chem; 2019 Feb; 164():366-377. PubMed ID: 30611056
[TBL] [Abstract][Full Text] [Related]
20. Combination of salinomycin and silver nanoparticles enhances apoptosis and autophagy in human ovarian cancer cells: an effective anticancer therapy.
Zhang XF; Gurunathan S
Int J Nanomedicine; 2016; 11():3655-75. PubMed ID: 27536105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
